Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
EV/Sales |
+7 more quarters Free account |
— | — | — | — |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.28 | 1.24 | 0.31 | 0.19 | |
Current Ratio |
1.39 | 1.25 | 0.58 | 0.22 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
4.46% | 4.11% | 209.72% | 177.99% | |
Debt/Equity |
0.08 | 0.08 | (1.08) | (0.70) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(5.21) | 0.00 | (2.84) | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | — | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(6.08) | (0.38) | (7.96) | — | |
Working Capital |
1.42 | 0.72 | (2.60) | (9.68) | |
Capital Expenditures |
(2.10) | — | (1.23) | — | |
Net Current Asset Value |
1.42 | 0.65 | (14.58) | (20.11) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
1.03 | 0.83 | 0.84 | 0.98 | |
Average Payables |
5.06 | 5.33 | 4.66 | 3.67 | |
Average Assets |
23.46 | 21.36 | 7.52 | 8.20 | |
Average Common Equity |
15.59 | 12.47 | (7.91) | (5.95) |
Columns are period end dates · fundamentals updated 2 Oct 2026